ArticleThe Prostate2025
Comparative Effectiveness of First-Line Treatments for Castration-Resistant Prostate Cancer: A Large-Scale Retrospective Study in Japan.
Article in The Prostate, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesProstate cancer is the fifth leading cause of cancer-related death in men worldwide, with particularly high mortality rates in countries with large Black populations, and the United States. Despite the prevalence of prostate cancer screening, advanced cases are still diagnosed, with 10%-20% of these progressing to castration-resistant prostate cancer (CRPC) within 5 years. The survival of patients with CRPC is limited, which emphasizes the need for effective treatment strategies.
methodsThe study utilized a database of Japanese DPC hospitals, comprising approximately 25.6% coverage. From April 2008 to December 2022, 410,000 patients with prostate cancer were identified, of whom 25,934 were diagnosed with CRPC. A subset of 20,177 patients who received treatment for CRPC was selected for further analyses. The study focused on three treatments: abiraterone acetate (ABI), enzalutamide (ENZ), and docetaxel (DOC), excluding other treatments due to relatively low patient numbers. The analysis included age, date of the diagnosis of CRPC, presence of bone metastasis, agent type, and prognosis.
resultsThe study enrolled 18,924 patients with CRPC who were treated with ENZ, ABI, or DOC as the first-line treatment. In the overall population, ENZ was associated with prolonged OS in comparison to ABI (HR: 0.903, p < 0.003). In patients with bone metastases, no significant difference was found in treatment efficacy between ABI and ENZ. Sequential therapy starting with ABI followed by ENZ did not result in a significant difference in time to treatment failure but was associated with a slight improvement in overall survival.
conclusionsThis retrospective study, based on a large-scale Japanese database, indicates that ENZ may be the most effective first-line treatment for Japanese patients with CRPC, especially given its favorable outcomes relative to other treatments. Despite the limitations in the data set, the findings support the use of ABI-ENZ sequential therapy, which may provide additional clinical benefits in terms of overall survival.
trial registrationN/A.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.